Gliome: Molekulare Marker für die Therapieentscheidung – Pro

Pro

Patienten mit gleicher histologischer Diagnose können ganz unterschiedliche Krankheitsverläufe erfahren. Gründe hierfür sind u. a., dass histologisch gleiche Entitäten (molekular-)biologisch unterschiedliche Erkrankungen darstellen können und dass Patienten mit einem bestimmten molekularen Profil anders auf spezifische Therapien ansprechen. Molekulare Marker oder allgemeiner Biomarker stellen die Grundlage einer stratifizierten und personalisierten, „maßgeschneiderten“ Medizin dar.

• Literatur

• 1 Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95
• 2 Wiestler B, Capper D, Sill M et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 2014; 128: 561-571
• 3 Sahm F, Reuss D, Koelsche C et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 2014; 128: 551-559
• 4 Bettegowda C, Agrawal N, Jiao Y et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333: 1453-1455
• 5 van den Bent MJ, Brandes AA, Taphoorn MJ et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31: 344-350
• 6 Cairncross G, Wang M, Shaw E et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31: 337-343
• 7 Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466
• 8 Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13: 707-715
• 9 Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13: 916-926
• 10 Wick W, Weller M, van den Bent M et al. MGMT testing – the challenges for biomarker-based glioma treatment. Nat Rev Neurol 2014; 10: 372-385
• 11 Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150-4154
• 12 Cairncross JG, Wang M, Jenkins RB et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014; 32: 783-790
• 13 Schumacher T, Bunse L, Pusch S et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014; (advance online publication)
• 14 Rohle D, Popovici-Muller J, Palaskas N et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340: 626-630
• 15 Choi C, Ganji SK, DeBerardinis RJ et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012; 18: 624-629
• 16 Jones DT, Hutter B, Jager N et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013; 45: 927-932
• 17 Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 4722-4729